Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Controlled, Randomized Phase 3 Trial Evaluating 12-month Kidney Function in Highly Sensitized (cPRA ≥99.9%) Kidney Tx Patients With Positive XM Against a Deceased Donor, Comparing Desensitization Using Imlifidase With SoC

NCT04935177 is registered in ClinicalTrials.gov with Hansa Biopharma AB as lead sponsor.

NCT NCT04935177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04935177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Controlled, Randomized Phase 3 Trial Evaluating 12-month Kidney Function in Highly Sensitized (cPRA ≥99.9%) Kidney Tx Patients With Positive XM Against a Deceased Donor, Comparing Desensitization Using Imlifidase With SoC
Lead sponsor
Hansa Biopharma AB
Phase
Phase 3
Overall status
Completed
Start date
October 14, 2021
Completion date
June 20, 2025
Enrollment
64 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation in highly sensitized patients